HPS-133 - The efficacy and safety of eliminating 5-Fluorouracil Bolus versus keeping 5-Fluorouracil Bolus from FOLFOX and FOLFIRI Regimen: A retrospective study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-133
• By: TSENG, Shih-Ting (Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical, Foundation, Taiwan, Republic of China)
• Co-author(s): Ms Shih-Ting Tseng (Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical, Foundation, New Taipei City, Taiwan, Republic of China)
  Ms Tzu-Rong Peng (Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical, Foundation, New Taipei City, Taiwan, Republic of China)
  Ms Hsiu-Lan Huang (Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical, Foundation, New Taipei City, Taiwan, Republic of China)
  
• Abstract:

  Introduction:
  FOLFOX and FOLFIRI are multidrug chemotherapy regimens that include 5-Fluorouracil (5-FU) and are commonly used to treat various cancers, such as colorectal and gastric cancer. However, the role of the 5-FU bolus in these regimens remains controversial. This study evaluates the differences in efficacy and safety between bolus and..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login